Copyright: ©Author(s) 2026.
World J Gastroenterol. Jul 28, 2026; 32(28): 121267
Published online Jul 28, 2026. doi: 10.3748/wjg.121267
Published online Jul 28, 2026. doi: 10.3748/wjg.121267
Table 4 Diagnostic performance of the combined test across different disease groups
| Disease group | Sensitivity (95%CI) | Specificity (95%CI) | PPV (95%CI) | NPV (95%CI) | LR+ | LR- | AUC (95%CI) |
| Adenoma | 65% (48.5%-78.8%) | 60% (43.5%-75%) | 61.9% (46.2%-76%) | 63.2% (46.6%-77.8%) | 1.63 (1.04-2.53) | 0.58 (0.36-0.95) | 0.662 (0.543-0.782) |
| CRC | 87.5% (73%-95.8%) | 60% (43.5%-75%) | 68.6% (54.9%-80.2%) | 82.8% (64.7%-93.2%) | 2.19 (1.47-3.26) | 0.21 (0.09-0.49) | 0.866 (0.784-0.949) |
| Presence of intestinal lesions | 76.3% (65.5%-84.7%) | 60% (43.5%-75%) | 79.2% (68.5%-87.2%) | 55.8% (40.6%-70.2%) | 1.91 (1.28-2.84) | 0.4 (0.25-0.63) | 0.764 (0.68-0.848) |
- Citation: Jing W, Qin L, Zhang XH, Pan F, Ren RR, Li Y, Zhang Y, Peng LH, Wang ZK, Zhang XL. Diagnostic efficacy of fecal calprotectin combined with a high-sensitivity quantitative fecal immunochemical test for colorectal tumors. World J Gastroenterol 2026; 32(28): 121267
- URL: https://www.wjgnet.com/1007-9327/full/v32/i28/121267.htm
- DOI: https://dx.doi.org/10.3748/wjg.121267